VRNA (Verona Pharma PLC) Volume dodolan mangsa ngarep perusahaan

Simbol resmi perusahaan Verona Pharma plc (VRNA)

The expected sales volume of Verona Pharma plc (VRNA) demonstrates an accumulation phase, with the parameter stabilizing at 0.22. The business model is based on the full outsourcing of production and research, which eliminates major capital expenditures. Management must now establish a distribution network for its blockbuster, creating a unique niche in lung therapy without pressure from generics.

VRNA - Volume dodolan sing dikarepake perusahaan Verona Pharma plc ing rentang 04.07.2022 - 18.10.2025

Ringkesan rincian data analitis Verona Pharma Inc. (VRNA)

- nilai saham lan prakiraan konsensus rega:
Ringkesan analitik perusahaan:veronapharma.com
Produk mawa merek Verona Pharma Corp

For fundamental asset screening, this indicator serves as a leading filter, allowing for the identification of undervalued companies prior to the publication of official reports. By analyzing the company's projected future revenue, an investor assesses current market demand in real time, which for Verona Pharma plc (VRNA) signifies stable commercialization potential for drugs in the protected US and European markets, shielded from geopolitical risks.

Analisis perusahaan pesaing

Prakiraan volume dodolan HLN|KVUE (Kenvue Inc) - Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Jyong Biotech MENS|Ligand Pharma - Prakiraan pendapatan perusahaan|AMRX - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan perrigo.com|ALVO (Alvotech SA) - Volume dodolan mangsa ngarep perusahaan|Prakiraan dodolan perusahaan Liquidia Technologies LQDA|GLPG (Galapagos N.V.) - Prakiraan volume dodolan|ANIP: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan Afrezza (MNKD)|Prakiraan volume dodolan amphastar.com (AMPH)|Prakiraan volume dodolan PCRX (pacira.com)|Pendapatan mangsa ngarep perusahaan SPRY|Theravance Biopharma Inc - Prakiraan volume dodolan|Dodolan mangsa ngarep perusahaan Aquestive Therapeutics AQST|SCPH: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Tectonic Therapeutic, Inc.|TNXP (tonixpharma.com) - Prakiraan volume dodolan|SXTC (China SXT Pharmaceuticals, Inc.) - Prakiraan volume pendapatan perusahaan|Prakiraan pendapatan perusahaan eupraxiapharma.com (EPRX)|Prakiraan volume pendapatan perusahaan BHST|Prakiraan pendapatan perusahaan eXoZymes EXOZ|Pendapatan mangsa ngarep perusahaan ORMP|ENTX - Prakiraan pendapatan perusahaan|HYFT: Prakiraan pendapatan perusahaan|ABVC BioPharma, Inc (ABVC) - Prakiraan pendapatan perusahaan|Cumberland Pharma - Pendapatan mangsa ngarep perusahaan|QNTM (Quantum BioPharma Corp) - Prakiraan volume dodolan|FibroGen, Inc. - Pendapatan sing dikarepake perusahaan|Prakiraan volume dodolan TELO|Dodolan mangsa ngarep perusahaan Rani Therapeutics Holdings, Inc.|Prakiraan pendapatan perusahaan Synergy CHC Corp. SNYR|Prakiraan volume dodolan rallybio.com RLYB|Lexaria Bioscience Corp. - Prakiraan volume dodolan|PULM: Prakiraan pendapatan perusahaan|PTHL (ftzy.com.cn) - Volume dodolan mangsa ngarep perusahaan|APM: Prakiraan volume pendapatan perusahaan|LYRA (Lyra Therapeutics Inc) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan IBO (Impact BioMedical)|Volume dodolan mangsa ngarep perusahaan TNFA (TNF Pharmaceuticals)|Prakiraan volume dodolan cbdMD Corp (YCBD)|Prakiraan volume dodolan PRFX (PainReform)|Dodolan mangsa ngarep perusahaan Auris Medical (CYTO)|LIPO - Prakiraan pendapatan perusahaan|Optinose (OPTN) - Volume dodolan mangsa ngarep perusahaan|Pieris (PIRS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan PROC (Procaps Group S.A.)|Volume dodolan mangsa ngarep perusahaan PTPI|QLI: Pendapatan mangsa ngarep perusahaan|Prakiraan pendapatan perusahaan acelyrin.com (SLRN)|TFFP (TFF Pharma) - Pendapatan mangsa ngarep perusahaan